Change in quality of life in patients with acromegaly after treatment with octreotide LAR: First application of AcroQoL in Korea

Sang Ouk Chin, Choon Hee Chung, Yoon Sok Chung, Byung Joon Kim, Hee Young Kim, In Ju Kim, Jung Guk Kim, Min Seon Kim, Seong Yeon Kim, Eunjig Lee, Ki Young Lee, Sung Woon Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: This study was designed to investigate changes in health-related quality of life (HRQoL) of patients with acromegaly in Korea after medical treatment with octreotide LAR using the validated Korean version of the acromegaly quality of life questionnaire (AcroQoL). Design: A prospective, open-label, single-arm study. Setting: 11 tertiary centres in Korea. Participants: 58 Korean patients (aged 21-72 years) who were newly diagnosed with acromegaly between 2009 and 2012 were prescribed octreotide LAR 20 mg at the time of enrolment. During 24 weeks of observation, AcroQoL survey questionnaires and measurement of growth hormone insulin-like growth factor 1(GH/IGF-I) were performed at baseline, week 12 and week 24. Main outcome measures: We assessed the HRQoL of Korean patients with acromegaly after medical treatment with octreotide LAR using the validated Korean version of the AcroQoL questionnaire. Results: Patients had a mean age of 47.2 years (29 males), and GH and IGF-I significantly decreased during the first 12 weeks (GH: 4.8 vs 1.9 μg/L, p<0.001; IGF-I: 497 vs 265 μg/L, p<0.001), but showed insignificant change at week 24 (GH: 2.3 μg/ L; IGF-I: 294 μg/L). Only AcroQoL scores for the psychological appearance subdomain showed a significant increase during the entire 24 weeks (p<0.05). The change in the psychological appearance subdomain of AcroQoL scores demonstrated a significant but weak negative correlation with change in IGF-I levels (r=-0.282, p=0.039). When patients were divided into two groups according to their disease activity at week 24 (controlled vs uncontrolled), there was no difference in AcroQoL scores, but the psychological appearance subdomain of the two groups appeared to change differently over the entire 24-week period ( p=0.047). Conclusions: Medical treatment with octreotide LAR in patients with acromegaly has a limited contribution to HRQoL as assessed by the AcroQoL.

Original languageEnglish
Article numbere006898
JournalBMJ open
Volume5
Issue number6
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Acromegaly
Octreotide
Korea
Quality of Life
Insulin-Like Growth Factor I
Therapeutics
Psychology
Surveys and Questionnaires
Somatomedins
Growth Hormone
Observation
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Chin, Sang Ouk ; Chung, Choon Hee ; Chung, Yoon Sok ; Kim, Byung Joon ; Kim, Hee Young ; Kim, In Ju ; Kim, Jung Guk ; Kim, Min Seon ; Kim, Seong Yeon ; Lee, Eunjig ; Lee, Ki Young ; Kim, Sung Woon. / Change in quality of life in patients with acromegaly after treatment with octreotide LAR : First application of AcroQoL in Korea. In: BMJ open. 2015 ; Vol. 5, No. 6.
@article{808f874f4c9c4423a2e25ce9f0f8eecd,
title = "Change in quality of life in patients with acromegaly after treatment with octreotide LAR: First application of AcroQoL in Korea",
abstract = "Objectives: This study was designed to investigate changes in health-related quality of life (HRQoL) of patients with acromegaly in Korea after medical treatment with octreotide LAR using the validated Korean version of the acromegaly quality of life questionnaire (AcroQoL). Design: A prospective, open-label, single-arm study. Setting: 11 tertiary centres in Korea. Participants: 58 Korean patients (aged 21-72 years) who were newly diagnosed with acromegaly between 2009 and 2012 were prescribed octreotide LAR 20 mg at the time of enrolment. During 24 weeks of observation, AcroQoL survey questionnaires and measurement of growth hormone insulin-like growth factor 1(GH/IGF-I) were performed at baseline, week 12 and week 24. Main outcome measures: We assessed the HRQoL of Korean patients with acromegaly after medical treatment with octreotide LAR using the validated Korean version of the AcroQoL questionnaire. Results: Patients had a mean age of 47.2 years (29 males), and GH and IGF-I significantly decreased during the first 12 weeks (GH: 4.8 vs 1.9 μg/L, p<0.001; IGF-I: 497 vs 265 μg/L, p<0.001), but showed insignificant change at week 24 (GH: 2.3 μg/ L; IGF-I: 294 μg/L). Only AcroQoL scores for the psychological appearance subdomain showed a significant increase during the entire 24 weeks (p<0.05). The change in the psychological appearance subdomain of AcroQoL scores demonstrated a significant but weak negative correlation with change in IGF-I levels (r=-0.282, p=0.039). When patients were divided into two groups according to their disease activity at week 24 (controlled vs uncontrolled), there was no difference in AcroQoL scores, but the psychological appearance subdomain of the two groups appeared to change differently over the entire 24-week period ( p=0.047). Conclusions: Medical treatment with octreotide LAR in patients with acromegaly has a limited contribution to HRQoL as assessed by the AcroQoL.",
author = "Chin, {Sang Ouk} and Chung, {Choon Hee} and Chung, {Yoon Sok} and Kim, {Byung Joon} and Kim, {Hee Young} and Kim, {In Ju} and Kim, {Jung Guk} and Kim, {Min Seon} and Kim, {Seong Yeon} and Eunjig Lee and Lee, {Ki Young} and Kim, {Sung Woon}",
year = "2015",
month = "1",
day = "1",
doi = "10.1136/bmjopen-2014-006898",
language = "English",
volume = "5",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "6",

}

Change in quality of life in patients with acromegaly after treatment with octreotide LAR : First application of AcroQoL in Korea. / Chin, Sang Ouk; Chung, Choon Hee; Chung, Yoon Sok; Kim, Byung Joon; Kim, Hee Young; Kim, In Ju; Kim, Jung Guk; Kim, Min Seon; Kim, Seong Yeon; Lee, Eunjig; Lee, Ki Young; Kim, Sung Woon.

In: BMJ open, Vol. 5, No. 6, e006898, 01.01.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Change in quality of life in patients with acromegaly after treatment with octreotide LAR

T2 - First application of AcroQoL in Korea

AU - Chin, Sang Ouk

AU - Chung, Choon Hee

AU - Chung, Yoon Sok

AU - Kim, Byung Joon

AU - Kim, Hee Young

AU - Kim, In Ju

AU - Kim, Jung Guk

AU - Kim, Min Seon

AU - Kim, Seong Yeon

AU - Lee, Eunjig

AU - Lee, Ki Young

AU - Kim, Sung Woon

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: This study was designed to investigate changes in health-related quality of life (HRQoL) of patients with acromegaly in Korea after medical treatment with octreotide LAR using the validated Korean version of the acromegaly quality of life questionnaire (AcroQoL). Design: A prospective, open-label, single-arm study. Setting: 11 tertiary centres in Korea. Participants: 58 Korean patients (aged 21-72 years) who were newly diagnosed with acromegaly between 2009 and 2012 were prescribed octreotide LAR 20 mg at the time of enrolment. During 24 weeks of observation, AcroQoL survey questionnaires and measurement of growth hormone insulin-like growth factor 1(GH/IGF-I) were performed at baseline, week 12 and week 24. Main outcome measures: We assessed the HRQoL of Korean patients with acromegaly after medical treatment with octreotide LAR using the validated Korean version of the AcroQoL questionnaire. Results: Patients had a mean age of 47.2 years (29 males), and GH and IGF-I significantly decreased during the first 12 weeks (GH: 4.8 vs 1.9 μg/L, p<0.001; IGF-I: 497 vs 265 μg/L, p<0.001), but showed insignificant change at week 24 (GH: 2.3 μg/ L; IGF-I: 294 μg/L). Only AcroQoL scores for the psychological appearance subdomain showed a significant increase during the entire 24 weeks (p<0.05). The change in the psychological appearance subdomain of AcroQoL scores demonstrated a significant but weak negative correlation with change in IGF-I levels (r=-0.282, p=0.039). When patients were divided into two groups according to their disease activity at week 24 (controlled vs uncontrolled), there was no difference in AcroQoL scores, but the psychological appearance subdomain of the two groups appeared to change differently over the entire 24-week period ( p=0.047). Conclusions: Medical treatment with octreotide LAR in patients with acromegaly has a limited contribution to HRQoL as assessed by the AcroQoL.

AB - Objectives: This study was designed to investigate changes in health-related quality of life (HRQoL) of patients with acromegaly in Korea after medical treatment with octreotide LAR using the validated Korean version of the acromegaly quality of life questionnaire (AcroQoL). Design: A prospective, open-label, single-arm study. Setting: 11 tertiary centres in Korea. Participants: 58 Korean patients (aged 21-72 years) who were newly diagnosed with acromegaly between 2009 and 2012 were prescribed octreotide LAR 20 mg at the time of enrolment. During 24 weeks of observation, AcroQoL survey questionnaires and measurement of growth hormone insulin-like growth factor 1(GH/IGF-I) were performed at baseline, week 12 and week 24. Main outcome measures: We assessed the HRQoL of Korean patients with acromegaly after medical treatment with octreotide LAR using the validated Korean version of the AcroQoL questionnaire. Results: Patients had a mean age of 47.2 years (29 males), and GH and IGF-I significantly decreased during the first 12 weeks (GH: 4.8 vs 1.9 μg/L, p<0.001; IGF-I: 497 vs 265 μg/L, p<0.001), but showed insignificant change at week 24 (GH: 2.3 μg/ L; IGF-I: 294 μg/L). Only AcroQoL scores for the psychological appearance subdomain showed a significant increase during the entire 24 weeks (p<0.05). The change in the psychological appearance subdomain of AcroQoL scores demonstrated a significant but weak negative correlation with change in IGF-I levels (r=-0.282, p=0.039). When patients were divided into two groups according to their disease activity at week 24 (controlled vs uncontrolled), there was no difference in AcroQoL scores, but the psychological appearance subdomain of the two groups appeared to change differently over the entire 24-week period ( p=0.047). Conclusions: Medical treatment with octreotide LAR in patients with acromegaly has a limited contribution to HRQoL as assessed by the AcroQoL.

UR - http://www.scopus.com/inward/record.url?scp=84937231356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937231356&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2014-006898

DO - 10.1136/bmjopen-2014-006898

M3 - Article

C2 - 26063564

AN - SCOPUS:84937231356

VL - 5

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 6

M1 - e006898

ER -